ADIPOQ and metabolic dysfunction-associated steatohepatitis: Low adiponectin levels were significantly associated with metabolic dysfunction and were reduced in patients with MASH, consistent with adiponectin’s protective role against liver steatosis and fibrosis [14,58,59,60].